Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Aug 19;16(16):2882.
doi: 10.3390/cancers16162882.

The Genetic Analysis and Clinical Therapy in Lung Cancer: Current Advances and Future Directions

Angela Rina  1   2 , Debora Maffeo  1   3 , Francesca Minnai  4 , Martina Esposito  4 , Maria Palmieri  1   3 , Viola Bianca Serio  1   3 , Diletta Rosati  1   3 , Francesca Mari  2   3 , Elisa Frullanti  1   3 , Francesca Colombo  4
Affiliations
Review

The Genetic Analysis and Clinical Therapy in Lung Cancer: Current Advances and Future Directions

Angela Rina et al. Cancers (Basel). .

Abstract

Lung cancer, including both non-small cell lung cancer and small cell lung cancer, remains the leading cause of cancer-related mortality worldwide, representing 18% of the total cancer deaths in 2020. Many patients are identified already at an advanced stage with metastatic disease and have a worsening prognosis. Recent advances in the genetic understanding of lung cancer have opened new avenues for personalized treatments and targeted therapies. This review examines the latest discoveries in the genetics of lung cancer, discusses key biomarkers, and analyzes current clinical therapies based on this genetic information. It will conclude with a discussion of future prospects and potential research directions.

Keywords: genetic discoveries; lung cancer; personalized treatments; target therapy.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Classification of Lung Cancers. Lung cancer is divided into two main categories: about 85% of non-small cell lung carcinoma (NSCLC) including the subtypes of adenocarcinoma, squamous cell carcinoma (SQ) and large cell carcinoma (LC) and about 10–15% of small cell lung carcinoma (SCLC). Only 1–2% of lung tumors are pulmonary carcinoid.
See this image and copyright information in PMC

References

    1. Sung H., Ferlay J., Siegel R.L., Laversanne M., Soerjomataram I., Jemal A., Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 2021;71:209–249. doi: 10.3322/caac.21660. - DOI - PubMed
    1. Siegel R.L., Miller K.D., Jemal A. Cancer statistics, 2020. CA Cancer J. Clin. 2020;70:7–30. doi: 10.3322/caac.21590. - DOI - PubMed
    1. GBD 2015 Tobacco Collaborators; Smoking prevalence and attributable disease burden in 195 countries and territories, 1990–2015: A systematic analysis from the Global Burden of Disease Study 2015. Lancet. 2017;390:1644. doi: 10.1016/S0140-6736(17)32559-X. - DOI - PMC - PubMed
    1. Powell H.A., Iyen-Omofoman B., Hubbard R.B., Baldwin D.R., Tata L.J. The association between smoking quantity and lung cancer in men and women. Chest. 2013;143:123–129. doi: 10.1378/chest.12-1068. - DOI - PubMed
    1. Doll R., Peto R., Boreham J., Sutherland I. Mortality in relation to smoking: 50 years’ observations on male British doctors. BMJ. 2004;328:1519. doi: 10.1136/bmj.38142.554479.AE. - DOI - PMC - PubMed